olfactory receptor family 51 subfamily R member 1 pseudogeneGenealiases: []
Q-omics provides the consensus-scored OR51R1P profile across patient tissues and cancer cell-line models. OR51R1P expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, OR51R1P is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, OR51R1P RNA expression shows 8,851 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, LUSC, and LSCC as cancer lineages where OR51R1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR51R1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR51R1P survival associations across molecular data types. OR51R1P RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR51R1P RNA expression–survival associations across cancer types. High OR51R1P expression shows unfavorable associations in MESO, HNSC, KICH, LGG and CHOL, but favorable associations in SKCM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for OR51R1P RNA expression.
This table summarizes OR51R1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for OR51R1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR51R1P shows lower tumor expression in LUSC. The LUSC box plot shows higher OR51R1P RNA expression in normal versus tumor tissue (log2 FC = −0.016, t-test p = .017).
This table shows molecular features associated with OR51R1P in patient tissues and cancer cell lines. In patient samples, OR51R1P shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
